A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group - PubMed (original) (raw)

• PMID: 426553
• PMCID: PMC1397020

Clinical Trial

A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group

No authors listed. Ann Surg. 1979 Feb.

Abstract

One hundred six patients with histologically confirmed pancreatic carcinoma were randomized to one of three radiation treatment programs: 1) radiation therapy alone to 6000 rads; 2) 6000 rads plus 6-FU; or, 3) 4000 rads plus 5-FU. Patient survival was the primary study parameter. Both 4000 rads plus 5-FU (p less than .02) and 6000 rads plus 5-FU (p less than .01) were associated with a significantly longer patient survival than 6000 rads alone. Respective median survivals were 36 weeks, 40 weeks, and 20 weeks. The survival difference between 4000 rads plus 5-FU and 6000 rads plus 5-FU was not statistically significant at the time point selected.

PubMed Disclaimer

Similar articles

• Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
  Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, Lavin PT, Livstone E, Spiro H, Knowlton A, Kalser M, Barkin J, Lessner H, Mann-Kaplan R, Ramming K, Douglas HO Jr, Thomas P, Nave H, Bateman J, Lokich J, Brooks J, Chaffey J, Corson JM, Zamcheck N, Novak JW. Moertel CG, et al. Cancer. 1981 Oct 15;48(8):1705-10. doi: 10.1002/1097-0142(19811015)48:8<1705::aid-cncr2820480803>3.0.co;2-4. Cancer. 1981. PMID: 7284971 Clinical Trial.
• Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma.
  Furuse J, Kinoshita T, Kawashima M, Ishii H, Nagase M, Konishi M, Nakagohri T, Inoue K, Ogino T, Ikeda H, Maru Y, Yoshino M. Furuse J, et al. Cancer. 2003 Mar 1;97(5):1346-52. doi: 10.1002/cncr.11165. Cancer. 2003. PMID: 12599244 Clinical Trial.
• Current approaches to multimodality management of advanced pancreatic cancer.
  Douglass HO. Douglass HO. Hepatogastroenterology. 1993 Oct;40(5):433-42. Hepatogastroenterology. 1993. PMID: 8270232 Review.
• The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.
  Carter SK, Comis RL. Carter SK, et al. Cancer Treat Rev. 1975 Sep;2(3):193-214. doi: 10.1016/s0305-7372(75)80003-x. Cancer Treat Rev. 1975. PMID: 1104163 Review. No abstract available.

Cited by

• Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.
  Desai NV, Sliesoraitis S, Hughes SJ, Trevino JG, Zlotecki RA, Ivey AM, George TJ Jr. Desai NV, et al. Cancer Med. 2015 Aug;4(8):1224-39. doi: 10.1002/cam4.444. Epub 2015 Mar 13. Cancer Med. 2015. PMID: 25766842 Free PMC article. Review.
• LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.
  Hong CS, Ho W, Zhang C, Yang C, Elder JB, Zhuang Z. Hong CS, et al. Cancer Biol Ther. 2015;16(6):821-33. doi: 10.1080/15384047.2015.1040961. Epub 2015 Apr 21. Cancer Biol Ther. 2015. PMID: 25897893 Free PMC article. Review.
• Preoperative chemoradiation for resectable and locally advanced adenocarcinoma of the pancreas.
  Evans DB. Evans DB. J Gastrointest Surg. 2001 Jan-Feb;5(1):2-5. doi: 10.1016/s1091-255x(01)80002-0. J Gastrointest Surg. 2001. PMID: 11370617 Review. No abstract available.
• Adjuvant treatment strategies for pancreatic cancer.
  Newman EA, Simeone DM, Mulholland MW. Newman EA, et al. J Gastrointest Surg. 2006 Jun;10(6):916-26. doi: 10.1016/j.gassur.2005.10.018. J Gastrointest Surg. 2006. PMID: 16769552 Review.
• Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
  Crane CH, Janjan NA, Evans DB, Wolff RA, Ballo MT, Milas L, Mason K, Charnsangavej C, Pisters PW, Lee JE, Lenzi R, Vauthey JN, Wong A, Phan T, Nguyen Q, Abbruzzese JL. Crane CH, et al. Int J Pancreatol. 2001;29(1):9-18. doi: 10.1385/IJGC:29:1:09. Int J Pancreatol. 2001. PMID: 11560155

References

1. 1. Cancer. 1973 Dec;32(6):1341-5 - PubMed
2. 1. Lancet. 1969 Oct 25;2(7626):865-7 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • PubMed Central
  • Wolters Kluwer